PECULIARITIES OF CYTOKINE REGULATION IN PATIENTS WITH MALIGNANT TUMORS OF THE CERVIX DURING CANCER THERAPY

D. K Kenbaeva; Z. A Manambaeva

doi:10.17816/onco39971

Russian Journal of Oncology ›› 2013, Vol. 18 ›› Issue (1) : 36 -38. DOI: 10.17816/onco39971

Articles

research-article

PECULIARITIES OF CYTOKINE REGULATION IN PATIENTS WITH MALIGNANT TUMORS OF THE CERVIX DURING CANCER THERAPY

Author information +

History +

PDF

Abstract

The study included 117 patients with cervical cancer stage IIB and III undergoing combined radiotherapy and also specific immunotherapy and adoptive immunotherapy. The dynamics of a number of cytokines content has been defined (interleukin-2, -6, -10, -12, tumor necrosis factor-alpha). There was a significant excess of anti-inflammatory factors over stimulators of proliferation and differentiation of lymphocytes against the reduction of almost all the interleukins. The degree of impairment was dependent on the stage of the tumor. Application of the treatment method, which includes a specific and adoptive immunotherapy, promoted activation of interleukin production and elimination of immunoregulatory imbalance.

Keywords

cervical cancer / specific immunotherapy / adoptive immunotherapy / cytokines

Cite this article

Download citation ▾

D. K Kenbaeva, Z. A Manambaeva. PECULIARITIES OF CYTOKINE REGULATION IN PATIENTS WITH MALIGNANT TUMORS OF THE CERVIX DURING CANCER THERAPY. Russian Journal of Oncology, 2013, 18(1): 36-38 DOI:10.17816/onco39971

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Franco E. L., Schlecht N. F., Saslow D. The epidemiology of cervical cancer. Cancer J. 2003; 9 (5): 348—59.

[2]	Морхов К. Ю. Химиолучевое лечение первично неоперабельного рака шейки матки. В кн.: Материалы IV Ежегодной онкологической конференции. М.; 2000; 1: 153—6.

[3]	Крамарева Н. Л., Сельков С. А., Ярмолинская М. И., Павлов О. В. Изучение роли цитокинов в патогенезе эндометриоза и выборе иммунокорригирующей терапии. Медицинская иммунология. 2002; 4 (2): 278—9.

[4]	Bermúdez-Morales V. H., Peralta-Zaragoza O., Madrid-Marina V. Gene therapy with cytokines against cervical cancer. Salud Públ. Méx. 2005; 47 (6): 458—68.

[5]	Dinarello C. A. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastas. Rev. 2006; 25 (3): 307—13.

[6]	Сенников С. В., Силков А. Н. Методы определения цитокинов. Цитокины и воспаление. 2005; 4 (1): 22—27.

[7]	Sangro B., Melero I., Qian C., Prieto J. Gene therapy of cancer based on interleukin 12. Curr. Gene Ther. 2005; 5 (6): 573—81.

[8]	SmythM. J., Cretney E., KershawM. H., Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004; 202: 275—93.

[9]	Mazzolini G., Melero I., Prieto J. Role of interleukin-12 in cancer immunotherapy. Medicina (B. Aires). 2004; 64 (1): 77—8.

[10]	Wadler S., Levy D., Frederickson H. L. et al, Eastern Cooperative Oncology Group. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol. Oncol. 2004; 92 (3): 957—64.

[11]	Dobrzycka B., Terlikowski S. J., Garbowicz M. et al. Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer. Folia Histochem. Cytobiol. 2009; 47 (4): 609—13.

[12]	Bertazza L., Mocellin S. The dual role of tumor necrosis factor (TNF) in cancer biology. Curr. Med. Chem. 2010; 17 (29): 3337—52.

[13]	Diakowska D., Markocka-Mqczka K., Grabowski K., Lewandowski A. Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. Exp. oncol. 2006; 28 (4): 319—22.